The emerging mechanisms of isoform-specific PI3K signalling

By B. Vanhaesebroeck, J. Guillermet‐Guibert, M. Graupera, B. Bilanges. Nature reviews. Molecular cell biology, 2010

1,769 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/91dcad71488dcf51118d1e6844bd4b3ea8fe1f03

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. D. Fruman
2. Qingxiang Zeng
3. Junjiang Liu
4. Jin Yang
5. J. Mu
6. Shuzhi Deng
7. T. Balla
8. Fanglong Wu

In Molecular Biology

1. T. Balla
2. D. Fruman
3. W. Cui
4. Qingxiang Zeng
5. Gautam Sethi
6. Junjiang Liu
7. Jin Yang
8. J. Mu

Citations in the corpus

• Phosphoinositides: tiny lipids with giant impact on cell regulation. (2013, background): “These enzymes also exist in three forms in mammalian cells: PI3KC2 , PI3KC2 , and PI3KC2 (1347, 1610).”
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “RTK overactivation in cancer Growth factor-mediated induction of RTKs [33] or GPCRs [34] usually initiates the canonical pathway that engenders the activation of AKT, resulting in plasma membrane localization and induction of one, or more isoforms of the class I PI3K family [35] (Fig.”
• Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, background): “PI3K, as an intracellular phosphatidylinositol kinase, encompasses p85 and p110.(117) Transmembrane growth factor receptors include epidermal growth factor receptor (EGFR), Gprotein-coupled estrogen receptor (GPER), VEGF, and insulin growth factor receptor 1, etc.”
• The PI3K pathway in human disease (2017, neutral): “Generation of mice with deletion or mutation of PI3K genes has been instrumental in delineating the unique and redundant functions of PI3K isoforms in mammalian cells and tissues (Ok-kenhaug, 2013; Vanhaesebroeck et al., 2010).”
• The PI3K/AKT pathway in obesity and type 2 diabetes (2018, background): “Meanwhile, RTKs and GPCRs also activates Ras to subsequently activates PI3K [14].”
• Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “One characteristic of GPCRs is that they recognize and respond to chemically distinct ligands to effectively activate PI3K/Akt signaling in different cells.(3,68) Moreover, GPCRs regulate cancer cell proliferation and survival, and their persistent activation affects mitotic and metabolic responses,”
• PI3K in cancer: divergent roles of isoforms, modes of activation, and therapeutic targeting (2014, background): “The myotubularin (MTM) family phosphatases MTM1 and MTMR2 remove the 3ʹ phos‐ phate from PtdIns(3)P, regulating the lipid products of class II and III PI3Ks15–18.”
• PI3K signalling: the path to discovery and understanding (2012, background): “, with Vps34–Vps15 being present in several distinct complexes (reviewed in Ref”
• Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination (2016, background): “1), which stimulates the conversion of membrane-bound phosphatidylinositol-(4,5)bisphosphate [PtdIns(4,5)P2; PIP2] to phosphatidylinositol-(3,4,5)trisphosphate [PtdIns(3,4,5)P3; PIP3] (Vanhaesebroeck et al., 2010; Thorpe et al., 2015).”
• Targeting cancer stem cell pathways for cancer therapy (2020, background): “353 AKT is a serine/threonine kinase that is expressed as three isoforms: AKT1, AKT2, and AKT3.”